A5063949681- Lipoproteins and Cardiovascular Health
- Coronary Interventions and Diagnostics
- Cancer, Lipids, and Metabolism
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Cerebrovascular and Carotid Artery Diseases
- Cardiovascular Function and Risk Factors
- Nuclear Receptors and Signaling
- PARP inhibition in cancer therapy
- Advanced X-ray and CT Imaging
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Computational Drug Discovery Methods
- Cardiovascular Disease and Adiposity
- Lipid metabolism and disorders
Pauls Stradiņš Clinical University Hospital
2022-2025
University of Latvia
2022
Introduction Insufficient statin/ezetimibe effectiveness for low-density lipoprotein cholesterol (LDL-C) reduction is not uncommon. A novel gene-silencing medication inclisiran has been introduced. Near-infrared spectroscopy (NIRS) allows to assess the dynamics of plaque lipid content in context optimal lipid-lowering pharmacotherapy. The aim this study was evaluate impact hypolipidaemic pharmacotherapy, including add-on inclisiran, on plasma profile and content. Methods This enrolled...
Abstract Background/Introduction Near-infrared spectroscopy (NIRS) allows to quantify lipid composition of coronary artery lesions. High plaque content has been associated with increased adverse cardiovascular event risk. Purpose Aim this study was evaluate atherosclerotic reduction in association low-density lipoprotein (LDL-C) lowering on the background intensive hypolipidaemic therapy. Methods NIRS investigation performed stable disease patients having 20-50% stenosis proximal or middle...
Abstract Background Low-density lipoprotein cholesterol (LDL-C) has a causal role in atherosclerotic cardiovascular disease. Genetic studies and variability individual response to lipid-lowering therapies suggest combining hypolipidaemic medications with different mechanisms of action. Purpose The aim this study was evaluate the effect triple inclisiran-based therapy patients not reaching LDL-C target on maximum statin/ezetimibe treatment. Methods This prospective enrolled 37 stable coronary...
Abstract Background/Introduction The benefits of lipid-lowering drug treatment for the secondary prevention coronary heart disease have been well-established by randomized, controlled trials. More evidence has now emerged to support use high-intensity low-density lipoprotein cholesterol (LDL-C) –lowering therapy including statine, ezetimibe, and PCSK9 inhibitors. Intravascular imaging, such as near-infrared spectroscopy (NIRS) can detect lipid-rich plaques. Virtual histology...